
    
      The purpose of this study will be to establish the safety profile and the maximum tolerated
      dose (MTD) of the anti-VEGFR-1 monoclonal antibody IMC-18F1 administered weekly, every other
      week, or every three weeks in patients with advanced solid tumors who have not responded to
      standard therapy or for whom no standard therapy is available.
    
  